

Dinamico e capace di adattarmi rapidamente ai cambiamenti del settore Farmaceutico e dei Dispositivi Medici.
Abile nel creare e mantenere sinergie tra team multidisciplinari, riuscendo a potenziare le capacità collettive per raggiungere obiettivi comuni con efficacia ed efficienza.
Professionista orientato al cliente con eccellenti capacità di problem solving e team management.
Attitudine alla leadership.
In collaborazione con il Centro Regionale di FarmacoVigilanza mi sono dedicato alla raccolta, identificazione, comprensione e valutazione delle schede di segnalazione di Reazioni Avverse, provenienti dai Responsabili di Farmacovigilanza delle Strutture Sanitarie della regione Campania.
1. Disease-Modifying Therapies (DMTs) in Pregnant and Lactating Women with Multiple Sclerosis: Analysis of Real-World Data from EudraVigilance Database
The purpose of study was to compare the safety profile of glatiramer with natalizumab, alemtuzumab and ocrelizumab in pregnant and lactating women affected by multiple sclerosis (MS).
Liberata Sportiello, Raffaella Di Napoli, Nunzia Balzano, Annamaria Mascolo, Rosanna Ruggiero, Luigi Di Costanzo, Davida Monaco, Giorgia Teresa Maniscalco and Annalisa Capuano
Pharmaceuticals 2023, 16, 1566.
N.pagine: 17
MDPI
2. Multisystem Inflammatory Syndrome in Children Following COVID-19 Vaccination: A Sex-Stratified Analysis of the VAERS Database Using Brighton Collaboration Criteria.
A descriptive analysis was performed of Individual Case Safety Reports (ICSRs) associated with anti COVID-19 vaccines and related to the pediatric population from 2020 to 2022. The present pharmacovigilance study aimed to describe cases of MIS-c following COVID-19 vaccination, stratified by sex, reported in the Vaccine Adverse Events Reporting System (VAERS).
Valerio Liguori, Alessia Zinzi, Mario Gaio, Consiglia Riccardi, Luigi Di Costanzo, Francesca Gargano, Claudia Carpentieri, Maria D’Elia, Francesca Futura Bernardi, Ugo Trama, Annalisa Capuano and Concetta Rafaniello.
Pharmaceuticals 2023, 16, 1231.
N. Pagine: 14
MDPI
3. A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database.
Evaluation of the 2905 ICSRs with axi-cel as the suspected drug that had been uploaded in the EudraVigilance database from 1 January 2018 to 31 December 2022. The adverse events most-frequently reported were Nervous system disorders (25.6%) and, among them, immune-effector-cell associated neurotoxicity syndrome, followed by Immune system disorders (23.1%), General disorders and administration site conditions (12.0%), Blood and lymphatic system disorders (7.2%).
Concetta Rafaniello, Valerio Liguori, Alessia Zinzi, Mario Gaio, Angela Falco, Luigi Di Costanzo, Francesca Gargano, Valentina Trimarco, Mauro Cataldi and Annalisa Capuano
Biomedicines 2023, 11, 2162.
N. Pagine: 15
MDPI
4. Hepatobiliary Adverse Reactions during Treatment with Cladribine: Analysis of Data from the European Spontaneous Reporting System
Cladribine belongs to the group of disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS). According to the highlights of a meeting held by the Pharmacovigilance Risk Assessment Committee (PRAC) on 14 January 2022, cladribine may be associated with the occurrence of liver injury, and thus liver function monitoring is recommended.
Elena Mirabela Veliscu, Valerio Liguori, Antonietta Anatriello, Giorgia Teresa Maniscalco, Andrea Cantone, Luigi Di Costanzo, Pasquale Stefanelli, Cristina Scavone and Annalisa Capuano.
Pharmaceuticals 2023, 16, 1071.
N. Pagine: 15
MDPI